Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
six
months ended in Mar. 2026, abrdn Life Sciences Investorsspent$0.0 Mil on purchasing property, plant, equipment.
It gained$0.0 Mil from selling property, plant, and equipment.
It spent$0.0 Mil on purchasing business.
It gained$0.0 Mil from selling business.
It spent$0.0 Mil on purchasing investments.
It gained$0.0 Mil from selling investments.
It paid$0.0Mil for net Intangibles purchase and sale.
And it paid$0.0 Mil for other investing activities.
In all, abrdn Life Sciences Investorsgained$0.0 Mil on investment activities in financial market and operating subsidiaries for the
six
months ended in Mar. 2026.
abrdn Life Sciences Investors's purchase of property, plant, equipment for the
six
months ended in Mar. 2026 was $0.0 Mil. It means abrdn Life Sciences Investors spent $0.0 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
abrdn Life Sciences Investors's sale of property, plant, equipment for the
six
months ended in Mar. 2026 was $0.0 Mil. It means abrdn Life Sciences Investors gained $0.0 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
abrdn Life Sciences Investors's purchase of business for the
six
months ended in Mar. 2026 was $0.0 Mil. It means abrdn Life Sciences Investors spent $0.0 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
abrdn Life Sciences Investors's sale of business for the
six
months ended in Mar. 2026 was $0.0 Mil. It means abrdn Life Sciences Investors gained $0.0 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
abrdn Life Sciences Investors's purchase of investment for the
six
months ended in Mar. 2026 was $0.0 Mil. It means abrdn Life Sciences Investors spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
abrdn Life Sciences Investors's sale of investment for the
six
months ended in Mar. 2026 was $0.0 Mil. It means abrdn Life Sciences Investors gained $0.0 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
abrdn Life Sciences Investors's net Intangibles purchase and sale for the
six
months ended in Mar. 2026 was $0.0 Mil.
It means abrdn Life Sciences Investors paid $0.0 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
abrdn Life Sciences Investors's cash from discontinued investing activities for the
six
months ended in Mar. 2026 was 0.0 Mil.
It means abrdn Life Sciences Investors paid $0.0 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
abrdn Life Sciences Investors's cash from other investing activities for the
six
months ended in Mar. 2026 was $0.0 Mil.
It means abrdn Life Sciences Investors paid $0.0 Mil for other investing activities.
abrdn Life Sciences Investors Cash Flow from Investing Related Terms
abrdn Life Sciences Investors Cash Flow from Investing Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors Cash Flow from Investing Chart
abrdn Life Sciences Investors Cash Flow from Investing Calculation
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
abrdn Life Sciences Investors's Cash Flow from Investing for the fiscal year that ended in Sep. 2025 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Investing of $0.0 Mil mean?
abrdn Life Sciences Investors (HQL) has a Cash Flow from Investing of $0.0 Mil as of Mar. 2026. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for abrdn Life Sciences Investors and its competitors.
Is abrdn Life Sciences Investors' Cash Flow from Investing too high?
abrdn Life Sciences Investors' current Cash Flow from Investing is $0.0 Mil. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' Cash Flow from Investing compare to MUJ and ACP?
abrdn Life Sciences Investors' Cash Flow from Investing of $0.0 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for an Asset Management company?
A good Cash Flow from Investing depends on the Asset Management industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for abrdn Life Sciences Investors and its competitors. abrdn Life Sciences Investors's current Cash Flow from Investing is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $19.76 — trading 68.1% below its estimated fair value. The current Cash Flow from Investing is $0.0 Mil. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current Cash Flow from Investing is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?
Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued.
The current stock price of $19.76 is trading 68.1% below its estimated GF Value™ of $62.01.
GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.
Key valuation signals for HQL:
Cash Flow from Investing: $0.0 Mil
GF Value™: $62.01 vs. price of $19.76 (68.1% below fair value)
No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score
Get the complete analysis for HQL
Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HQL has been successfully added to your 
